Dr. med. Thomas Ruhstaller
Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
Tausch C, Däster K, Hayoz S, Matrai Z, Fitzal F, Henke G, Zwahlen D, Gruber G, Zimmermann F, Andreozzi M, Goldschmidt M, Schulz C, Maggi N, Saccilotto R, Heidinger M, Müller A, Tampaki E, Bjelic-Radisic V, Sávolt Á, Smanykó V, Hagen D, Müller D, Gnant M, Loibl S, Markellou P, Bekes I, Egle D, Ruhstaller T, Muenst S, Kümmel S, Vrieling C, Satler R, Becciolini C, Bucher S, Kurzeder C, Simonson C, Fehr P, Gabriel N, Maráz R, Sarlos D, Dedes K, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer C, Montagna G, Reitsamer R, Winkler J, Lam G, Fehr M, Naydina T, Kohlik M, Clerc K, Ostapenko V, Lelièvre L, Heil J, Knauer M, Weber W. Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). Breast Cancer Res Treat 2023; 201:215-225.
25.06.2023Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
25.06.2023Breast Cancer Res Treat 2023; 201:215-225
Tausch Christoph, Däster Kavitha, Hayoz Stefanie, Matrai Zoltan, Fitzal Florian, Henke Guido, Zwahlen Daniel Rudolf, Gruber Günther, Zimmermann Frank, Andreozzi Mariacarla, Goldschmidt Maite, Schulz Christina-Alexandra, Maggi Nadia, Saccilotto Ramon, Heidinger Martin, Müller Andreas S, Tampaki Ekaterini Christina, Bjelic-Radisic Vesna, Sávolt Ákos, Smanykó Viktor, Hagen Daniela, Müller Dieter J, Gnant Michael, Loibl Sibylle, Markellou Pagona, Bekes Inga, Egle Daniel, Ruhstaller Thomas, Muenst Simone, Kümmel Sherko, Vrieling Conny, Satler Rok, Becciolini Charles, Bucher Susanne, Kurzeder Christian, Simonson Colin, Fehr Peter Martin, Gabriel Natalie, Maráz Robert, Sarlos Dimitri, Dedes Konstantin Johannes, Leo Cornelia, Berclaz Gilles, Fansa Hisham, Hager Christopher, Reisenberger Klaus, Singer Christian F, Montagna Giacomo, Reitsamer Roland, Winkler Jelena, Lam Giang Thanh, Fehr Mathias Konrad, Naydina Tatiana, Kohlik Magdalena, Clerc Karine, Ostapenko Valerijus, Lelièvre Loic, Heil Jörg, Knauer Michael, Weber Walter Paul
Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial.
Panje C, Hayoz S, Eisterer W, Hess V, Thuss-Patience P, Schacher S, Dürr D, Wagner A, Girschikofsky M, Eboulet E, Stahl M, Ruhstaller T. Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial. Eur J Cancer 2022; 177:186-193.
05.10.2022Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial.
05.10.2022Eur J Cancer 2022; 177:186-193
Panje Cédric, Hayoz Stefanie, Eisterer Wolfgang, Hess Viviane, Thuss-Patience Peter, Schacher Sabina, Dürr Donat, Wagner Anna Dorothea, Girschikofsky Michael, Eboulet Eric I, Stahl Michael, Ruhstaller Thomas
Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methods.
Hitz F, Ribi K, Grote G, Kolbe M, Schmitz C, Lamb B, Ruhstaller T, Berchtold P, Sevdalis N. Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methods. Cancer Rep (Hoboken) 2021; 5:e1541.
28.09.2021Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methods.
28.09.2021Cancer Rep (Hoboken) 2021; 5:e1541
Hitz Felicitas, Ribi Karin, Grote Gudela, Kolbe Michaela, Schmitz Christof, Lamb Benjamin W, Ruhstaller Thomas, Berchtold Peter, Sevdalis Nick
Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Knauer M, Winkler J, Reinisch M, Reitsamer R, Singer C, Reisenberger K, Hager C, Fansa H, Exner R, Dubsky P, Berclaz G, Leo C, Lam G, Fehr M, Naydina T, Heil J, Egle D, Lelièvre L, Markellou P, Schulz A, Maggi N, Nussbaumer R, Fitzal F, Ostapenko V, Clerc K, Kohlik M, Dedes K, Sarlos D, Muenst S, Ruhstaller T, Maddox C, Seiler S, Zimmermann F, Gruber G, Zwahlen D, Henke G, Tausch C, Hayoz S, Matrai Z, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Maráz R, Gabriel N, Fehr P, Simonson C, Bucher S, Becciolini C, Meyer I, Satler R, Vrieling C, Újhelyi M, Kurzeder C, Weber W. Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). Breast 2021; 60:98-110.
08.09.2021Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
08.09.2021Breast 2021; 60:98-110
Knauer Michael, Winkler Jelena, Reinisch Mattea, Reitsamer Roland, Singer Christian F, Reisenberger Klaus, Hager Christopher, Fansa Hisham, Exner Ruth, Dubsky Peter, Berclaz Gilles, Leo Cornelia, Lam Giang Thanh, Fehr Mathias K, Naydina Tatiana, Heil Jörg, Egle Daniel, Lelièvre Loic, Markellou Pagona, Schulz Alexandra, Maggi Nadia, Nussbaumer Rahel, Fitzal Florian, Ostapenko Valerijus, Clerc Karine, Kohlik Magdalena, Dedes Konstantin J, Sarlos Dimitri, Muenst Simone, Ruhstaller Thomas, Maddox Charlotte, Seiler Stefanie, Zimmermann Frank, Gruber Günther, Zwahlen Daniel R, Henke Guido, Tausch Christoph, Hayoz Stefanie, Matrai Zoltan, Ackerknecht Markus, Kuemmel Sherko, Bjelic-Radisic Vesna, Maráz Robert, Gabriel Natalie, Fehr Peter M, Simonson Colin, Bucher Susanne, Becciolini Charles, Meyer Inna, Satler Rok, Vrieling Conny, Újhelyi Mihály, Kurzeder Christian, Weber Walter P
Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase lll Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08)
von Holzen U, Függer R, Königsrainer A, Gloor B, Furrer M, Gerard M, Hawle H, Walz M, Alesina P, Schäfer M, Marti W, Kettelhack C, Schmidt S, Hayoz S, Steffen T, Grieder F, Bartsch D, Schnider A, Knoefel W, Piessen G, Ruhstaller T. Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase lll Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08). Ann Surg 2020
26.08.2020Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase lll Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08)
26.08.2020Ann Surg 2020
von Holzen Urs, Függer Reinhold, Königsrainer Alfred, Gloor Beat, Furrer Markus, Gerard Marie-Aline, Hawle Hanne, Walz Martin K, Alesina Piero, Schäfer Markus, Marti Walter R, Kettelhack Christoph, Schmidt Sven, Hayoz Stefanie, Steffen Thomas, Grieder Felix, Bartsch Detlef, Schnider Annelies, Knoefel Wolfram-Trudo, Piessen Guillaume, Ruhstaller Thomas
Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer
Maranta A, Broder S, Fritzsche C, Knauer M, Thürlimann B, Jochum W, Ruhstaller T. Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. Breast 2020; 51:120-126.
23.03.2020Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer
23.03.2020Breast 2020; 51:120-126
Maranta Angela Fischer, Broder Simon, Fritzsche Constanze, Knauer Michael, Thürlimann Beat, Jochum Wolfram, Ruhstaller Thomas
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
Eppenberger-Castori S, Klingbiel D, Ruhstaller T, Dietrich D, Rufle D, Rothgiesser K, Pagani O, Thürlimann B. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99. BMC cancer 2020; 20:114.
11.02.2020Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
11.02.2020BMC cancer 2020; 20:114
Eppenberger-Castori Serenella, Klingbiel Dirk, Ruhstaller Thomas, Dietrich Daniel, Rufle Daniel Alexander, Rothgiesser Karin, Pagani Olivia, Thürlimann Beat
Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
Varga Z, Thürlimann B, Klingbiel D, Hawle H, Tille J, Rau T, Perriard U, Jochum W, Li Q, Ruhstaller T. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Sci Rep 2019; 9:13534.
19.09.2019Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
19.09.2019Sci Rep 2019; 9:13534
Varga Zsuzsanna, Thürlimann Beat, Klingbiel Dirk, Hawle Hanne, Tille Jean-Christoph, Rau Tilman, Perriard Ulrike, Jochum Wolfram, Li Qiyu, Ruhstaller Thomas
Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy
Panje C, Plasswilm L, Ruhstaller T, Gerard M, Hawle H, Schacher S, Henke G, Meier U, Garcia Schüler H, Herrmann E, Baracos V, Hayoz S, Höng L, Swiss Group for Clinical Cancer Research (SAKK). Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. Radiat Oncol 2019; 14:166.
11.09.2019Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy
11.09.2019Radiat Oncol 2019; 14:166
Panje Cédric, Plasswilm Ludwig, Ruhstaller Thomas, Gerard Marie-Aline, Hawle Hanne, Schacher Sabina, Henke Guido, Meier Urs R, Garcia Schüler Helena, Herrmann Evelyn, Baracos Vickie E, Hayoz Stefanie, Höng Laura, Swiss Group for Clinical Cancer Research (SAKK)
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Schmid S, Zaman K, Weder P, von Moos R, Thürlimann B, Rochlitz C, Pestalozzi B, Pagani O, Oehlschlegel C, Nolè F, Munzone E, Mamot C, Goldhirsch A, Aebi S, Klingbiel D, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC cancer 2019; 19:902.
10.09.2019Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
10.09.2019BMC cancer 2019; 19:902
Schmid Sabine, Zaman Khalil, Weder Patrik, von Moos Roger, Thürlimann Beat, Rochlitz Christoph, Pestalozzi Bernhard, Pagani Olivia, Oehlschlegel Christian, Nolè Franco, Munzone Elisabetta, Mamot Christoph, Goldhirsch Aron, Aebi Stefan, Klingbiel Dirk, Ruhstaller Thomas
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
Gargiulo P, Pignata S, Berardi S, Glimelius B, Scheithauer W, Ruhstaller T, Bodoky G, Herrmann R, Dietrich D, Brauchli P. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. Ther Adv Med Oncol 2019; 11:1758835918818351.
02.01.2019Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
02.01.2019Ther Adv Med Oncol 2019; 11:1758835918818351
Gargiulo Piera, Pignata Sandro, Berardi Simona, Glimelius Bengt, Scheithauer Werner, Ruhstaller Thomas, Bodoky György, Herrmann Richard, Dietrich Daniel, Brauchli Peter
Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial
Henke G, Kurzeder C, Gyr A, Ballardini B, Matrai Z, Gnant M, Fitzal F, Hawle H, Ackerknecht M, Muenst S, Zwahlen D, Ruhstaller T, Gerard M, Hayoz S, Ribi K, Knauer M, Weber W. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials 2018; 19:667.
04.12.2018Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial
04.12.2018Trials 2018; 19:667
Henke Guido, Kurzeder Christian, Gyr Andreas, Ballardini Bettina, Matrai Zoltan, Gnant Michael, Fitzal Florian, Hawle Hanne, Ackerknecht Markus, Muenst Simone, Zwahlen Daniel R, Ruhstaller Thomas, Gerard Marie-Aline, Hayoz Stefanie, Ribi Karin, Knauer Michael, Weber Walter P
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Ruhstaller T, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber R, Coates A, Goldhirsch A, Thürlimann B, Regan M, Veyret C, Del Mastro L, Giobbie-Hurder A, Colleoni M, Jensen M, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen E, Gladieff L, Bonnefoi H, Harvey V, Spazzapan S, Tondini C, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol 2018:JCO1800440.
26.11.2018Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
26.11.2018J Clin Oncol 2018:JCO1800440
Ruhstaller Thomas, Simoncini Edda, Gianni Lorenzo, Rochlitz Christoph, Kralidis Elena, Zaman Khalil, Jassem Jacek, Piccart-Gebhart Martine, Di Leo Angelo, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Thürlimann Beat, Regan Meredith M, Veyret Corinne, Del Mastro Lucia, Giobbie-Hurder Anita, Colleoni Marco, Jensen Maj-Britt, Ejlertsen Bent, de Azambuja Evandro, Neven Patrick, Láng István, Jakobsen Erik Hugger, Gladieff Laurence, Bonnefoi Hervé, Harvey Vernon J, Spazzapan Simon, Tondini Carlo, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
Preusser M, De Mattos-Arruda L, Thill M, Criscitiello C, Bartsch R, Ruhstaller T, de Azambuja E, Zielinski C. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. ESMO Open 2018; 3:e000368.
20.08.2018CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
20.08.2018ESMO Open 2018; 3:e000368
Preusser Matthias, De Mattos-Arruda Leticia, Thill Marc, Criscitiello Carmen, Bartsch Rupert, Ruhstaller Thomas, de Azambuja Evandro, Zielinski Christoph C
Reply to the letter to the editor "Anti-EGFR therapy in oesophagogastric cancer: precise but not enough" by M. Salati and S. Cascinu
Ruhstaller T, Langer R, Thuss-Patience P, Eisterer W, Stahl M. Reply to the letter to the editor "Anti-EGFR therapy in oesophagogastric cancer: precise but not enough" by M. Salati and S. Cascinu. Ann Oncol 2018
09.07.2018Reply to the letter to the editor "Anti-EGFR therapy in oesophagogastric cancer: precise but not enough" by M. Salati and S. Cascinu
09.07.2018Ann Oncol 2018
Ruhstaller Thomas, Langer R, Thuss-Patience P, Eisterer W, Stahl M
Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial
Weber W, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal S, Ruhstaller T, Fehr P, Knauer M, Pioch V, Güth U, Hess T, Tausch C, Hayoz S, Fehr M, Ribi K, Hawle H, Lupatsch J, Matter-Walstra K, Chiesa F, Dedes K, Berclaz G, Lelièvre L, Swiss Group for Clinical Cancer Research (SAKK). Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial. Ann Surg Oncol 2018; 25:2632-2640.
08.06.2018Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial
08.06.2018Ann Surg Oncol 2018; 25:2632-2640
Weber Walter Paul, Sarlos Dimitri, Leo Cornelia, Canonica Claudia, Gabriel Natalie, Zeindler Jasmin, Cassoly Estelle, Andrieu Christiane, Soysal Savas Deniz, Ruhstaller Thomas, Fehr Peter Martin, Knauer Michael, Pioch Verena, Güth Uwe, Hess Thomas, Tausch Christoph, Hayoz Stefanie, Fehr Mathias Konrad, Ribi Karin, Hawle Hanne, Lupatsch Judith Eva, Matter-Walstra Klazien, Chiesa Federica, Dedes Konstantin Johannes, Berclaz Gilles, Lelièvre Loic, Swiss Group for Clinical Cancer Research (SAKK)
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis P, Pavesi L, Ruhstaller T, Davidson N, Coleman R, Debled M, Buchholz S, Ingle J, Winer E, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates A, Gelber R, Goldhirsch A, Regan M, Climent M, Spazzapan S, Puglisi F, Pagani O, Fleming G, Walley B, Colleoni M, Láng I, Gomez H, Tondini C, Ciruelos E, Burstein H, Bonnefoi H, Bellet M, Martino S, Geyer C, Goetz M, Stearns V, Pinotti G, SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 2018; 379:122-137.
04.06.2018Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
04.06.2018N Engl J Med 2018; 379:122-137
Francis Prudence A, Pavesi Lorenzo, Ruhstaller Thomas, Davidson Nancy E, Coleman Robert, Debled Marc, Buchholz Stefan, Ingle James N, Winer Eric P, Maibach Rudolf, Rabaglio-Poretti Manuela, Ruepp Barbara, Di Leo Angelo, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Regan Meredith M, Climent Miguel A, Spazzapan Simon, Puglisi Fabio, Pagani Olivia, Fleming Gini F, Walley Barbara A, Colleoni Marco, Láng István, Gomez Henry L, Tondini Carlo, Ciruelos Eva, Burstein Harold J, Bonnefoi Hervé R, Bellet Meritxell, Martino Silvana, Geyer Charles E, Goetz Matthew P, Stearns Vered, Pinotti Graziella, SOFT and TEXT Investigators and the International Breast Cancer Study Group
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
Ruhstaller T, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol 2018; 29:1386-1393.
01.06.2018Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
01.06.2018Ann Oncol 2018; 29:1386-1393
Ruhstaller Thomas, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S C, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J R, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00
Munzone E, Barberis M, Goldhirsch A, Regan M, Gelber R, Coates A, Di Leo A, Viale G, Kammler R, Gianni L, Ruhstaller T, Láng I, Guerini-Rocco E, Fumagalli C, Gray K, Colleoni M. Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. Breast Cancer Res Treat 2018; 170:351-360.
27.03.2018Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00
27.03.2018Breast Cancer Res Treat 2018; 170:351-360
Munzone Elisabetta, Barberis Massimo, Goldhirsch Aron, Regan Meredith M, Gelber Richard D, Coates Alan S, Di Leo Angelo, Viale Giuseppe, Kammler Roswitha, Gianni Lorenzo, Ruhstaller Thomas, Láng István, Guerini-Rocco Elena, Fumagalli Caterina, Gray Kathryn P, Colleoni Marco
Vitamin D levels in Swiss breast cancer survivors
Baumann M, Templeton A, Ruhstaller T, Riesen W, Mark M, Klingbiel D, Hochstrasser A, Dietrich D, Dani S, Thürlimann B. Vitamin D levels in Swiss breast cancer survivors. Swiss Med Wkly 2018; 148:w14576.
29.01.2018Vitamin D levels in Swiss breast cancer survivors
29.01.2018Swiss Med Wkly 2018; 148:w14576
Baumann Michael, Templeton Arnoud J, Ruhstaller Thomas, Riesen Walter F, Mark Michael Thomas, Klingbiel Dirk, Hochstrasser Andreas, Dietrich Daniel, Dani Sergio Ulhoa, Thürlimann Beat